All In Biotech

Drug Trial Radar · NCT00703755

A Randomized, Double-Blind Trial Comparing the Efficacy and Safety of Fenofibrate, Metformin, Their Combination and Placebo in Patients With Metabolic Syndrome.

Last checked: Nov 20, 2026Latest source record: Jun 25, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 2,288 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,288

Actual

Start

Mar 2003

Primary completion

Jun 2004

Study completion Jun 2004

Sponsor

Lead sponsor
Solvay PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Jun 23, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Factorial
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to study the effect of different combinations of fenofibrate and metformin on the cluster of metabolic syndrome (MetS) biochemical abnormalities, and to determine the dose combination allowing normalization of MetS patients.

Conditions

  • Patients With Metabolic Syndrome

Interventions

  • Fenofibrate /MetforminDrug

    fenofibrate 2 x 40 mg bid + metformin 850 mg bid (F160-M1700)

  • Fenofibrate /MetforminDrug

    fenofibrate 2 x 40 mg bid + metformin 500 mg bid (F160-M1000)

  • Fenofibrate /MetforminDrug

    fenofibrate 40 mg bid + metformin 850 mg bid (F80-M1700)

  • Fenofibrate /MetforminDrug

    fenofibrate 40 mg bid + metformin 500 mg bid (F80-M1000)

  • Fenofibrate /MetforminDrug

    fenofibrate 2 x 40 mg bid + metformin placebo (F160-M0)

  • Fenofibrate /MetforminDrug

    fenofibrate placebo + metformin 850 mg bid (F0-M1700)

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The percentage of normalized patients at V4 (fasting glucose < 6.1 mmol/L, TG < 1.69 mmol/L and HDL-C >= 1.03 mmol/L in males and >= 1.29 mmol/L in females)Time frame: End of study visit (V4)

Locations

101 sites in 9 countries. Site status is shown where the registry gives one.

  • Site 007

    Chicoutimi, Canada

  • Site 024

    Halifax, Canada

  • Site 004

    Hamilton, Canada

  • Site 012

    Kingston, Canada

  • Site 017

    Longueuil, Canada

  • Site 009

    Montague, Canada

  • Site 001

    Montreal, Canada

  • Site 015

    Montreal, Canada

  • Site 003

    Québec, Canada

  • Site 025

    Sainte-Foy, Canada

  • Site 026

    Sainte-Foy, Canada

  • Site 021

    Sherbrooke, Canada

  • Site 010

    St. John's, Canada

  • Site 020

    St. John's, Canada

  • Site 022

    St. John's, Canada

  • Site 006

    Ste-Foy, Canada

  • Site 016

    Toronto, Canada

  • Site 005

    Vancouver, Canada

  • Site 011

    Victoria, Canada

  • Site 013

    Calgary, Alberta, Canada

  • Site 019

    Calgary, Alberta, Canada

  • Site 090

    Hus, Finland

  • Site 091

    Jakobstad, Finland

  • Site 095

    Jyväskylä, Finland

  • Site 092

    Mikkeli, Finland

  • Site 096

    Närpes, Finland

  • Site 094

    Vaasa, Finland

  • Site 190

    Budapest, Hungary

  • Site 191

    Budapest, Hungary

  • Site 193

    Budapest, Hungary

  • Site 199

    Budapest, Hungary

  • Site 202

    Budapest, Hungary

  • Site 204

    Budapest, Hungary

  • Site 203

    Debrecen, Hungary

  • Site 200

    Gyöngyös, Hungary

  • Site 201

    Győr, Hungary

  • Site 198

    Gyula, Hungary

  • Site 197

    Miskolc, Hungary

  • Site 196

    Pécs, Hungary

  • Site 194

    Szeged, Hungary

Showing 40 of 101 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.